Proviron

Proviron (generic mesterolone) is an oral androgen derived from DHT that’s been used medically for male androgen deficiency and sometimes in fertility/sexual-function contexts. Pharmacologically, it’s an androgen receptor (AR) agonist, tends to be more “androgenic” than anabolic, and it’s unusual among oral androgens in that it’s not aromatized to estrogen (so it doesn’t directly raise estradiol the way testosterone can). (NCBI)

A key “practical” feature people talk about is that mesterolone has high SHBG binding affinity, which can displace some testosterone from SHBG and (in theory) increase free testosterone fraction in some situations—one reason it’s often framed as a “libido / androgen tone” lever rather than a mass-building drug. It’s also commonly described as having lower hepatotoxicity risk than many 17α-alkylated oral steroids, though lipid/cardiovascular risk signals still matter.

Anecdotes (Community Reports):

https://www.reddit.com/r/FinasterideSyndrome/comments/1n08ejb/protocol_im_doing_provirone2/

https://www.reddit.com/r/FinasterideSyndrome/comments/1g8vv3w/crashed_on_proviron_what_next/

https://www.reddit.com/r/PSSD/comments/tf4m1s/5_five_steroidbased_recovery_stories/

How to Interpret This Page

This page summarizes community anecdotes and informal observations, not medical evidence. “Improvement” means a person reported feeling better after an intervention; it does not prove the intervention caused the change or that it will apply to others. Outcomes can be influenced by many factors (time, stopping another trigger, dose changes, other interventions, sleep/diet), and reporting bias is common. Some substances mentioned in improvement stories are also linked to flares or worsening in other reports. Use this as a starting point for research and discussion with a licensed clinician—not as medical advice.

Community Reports: Mixed Outcomes & Variable Risk Signal

Why it’s discussed (potential overlap): In PFS/PSSD/PAS circles, Proviron usually comes up as a “direct AR tone” intervention—DHT-like signaling without aromatization—sometimes framed as potentially helpful for libido/sexual function, mood/drive, or as part of broader hormone “reset” approaches. You also see occasional standout anecdotes claiming major improvement or even “recovery,” which is why it stays on the radar.

What people actually report: The overall pattern is mixed: some describe partial symptom improvement (often libido/ED-related or “drive/energy” type changes), many describe no durable change, and a subset describe worsening(commonly framed as emotional blunting/anhedonia shifts, irritability/anxiety, sleep disruption, or sexual changes). A reasonable way to present this is: Proviron can strongly push androgen signaling (and alter binding dynamics), but PFS/PSSD symptoms don’t reliably track simple androgen increases, so results are unpredictable.

Reasons for caution (non-PFS-specific safety + “sensitized system” issues): Proviron is not a benign supplement—it's an androgenic drug. Side effects and risks discussed in medical references include androgenic effects (acne/hair effects/libido changes), and research on anabolic–androgenic steroids including mesterolone shows unfavorable lipid changes in some settings (a cardiovascular risk signal). Product quality/sourcing also matters if it’s obtained outside standard medical channels. (PMC)
Also worth noting: clinical literature on sexual-function outcomes with mesterolone exists but is not uniformly dramatic (i.e., not a guaranteed “sexual function fix”), which fits the community’s “variable response” pattern.

Evidence basis

Established androgen pharmacology (AR agonism; DHT-derivative; not aromatized; SHBG binding properties) plus limited clinical studies in hypogonadal/sexual-function contexts; general AAS safety literature (including lipid effects); and anecdotal PFS/PSSD/PAS community reports describing mixed outcomes (improvement, no effect, worsening).